Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10910841 | Lung Cancer | 2015 | 6 Pages |
Abstract
ObjectivesThe modest benefits from concurrent chemoradiotherapy (CCRT) in patients with stage III non-small cell lung cancer (NSCLC) warrant a more effective treatment regimen. We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC.Materials and MethodsEligible patients were treated with weekly cetuximab (initial dose 400Â mg/m2, day 1, week 1; maintenance dose 250Â mg/m2 from week 2 to the end of CCRT) and induction vinorelbine (25Â mg/m2, days 1 and 8) and cisplatin (75Â mg/m2, day 1) every 3 weeks for 2 cycles from week 2. Concomitant thoracic radiation (60-66Â Gy/2Â Gy) and two cycles of NP (vinorelbine 12.5Â mg/m2, days 1 and 8; cisplatin 25Â mg/m2, days 1 to 3, every 3 weeks) were started from week 7. The primary endpoints were toxicities; the secondary endpoints encompassed response rate and survival.ResultsIn total, 27 patients were enrolled, and 24 completed the full regimen. No treatment-related death occurred. Severe (CTCAE Grade 3 or high) adverse events were experienced by 81% patients (22/27), mostly haematologic. Severe non-haematologic toxicities including nausea/vomiting, intestinal obstruction, pulmonary infection and esophagitis, each of which was detected in <7% of patients. With a median follow-up of 26.7 months, the median survival was 26.7 months, with 1- and 2-year survival rates of 88.9% and 51.9%, respectively. Six patients remained progression-free to date, and the median progression-free survival was 13.5 months. The overall response rate was 63% and 77.8% after the induction and CCRT phases, respectively.ConclusionWeekly cetuximab with induction vinorelbine/cisplatin followed by concurrent cetuximab vinorelbine/cisplatin thoracic radiation is feasible with a manageable toxicity profile and clinically active.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Di Liu, Xiao Zheng, Jiayan Chen, Guan Liu, Yaping Xu, Yuxin Shen, Liyi Xie, Weixin Zhao, Guoliang Jiang, Min Fan,